| Ma, Ding |
L-MOCA, NCT03534453: Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy |
|
|
| Active, not recruiting | 3 | 229 | RoW | Olaparib 300mg tablets | AstraZeneca | Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy, Platinum Sensitive | 12/24 | 12/24 | | |
BGB-290-302, NCT03519230: Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer |
|
|
| Active, not recruiting | 3 | 224 | RoW | Pamiparib capsule, BGB-290, Placebo capsule | BeiGene | Ovarian Cancer | 06/25 | 06/26 | | |
|
|
NCT04723875: Postoperative Adjuvant Chemotherapy in Early-stage Cervical Cancer That Not Meet Criteria of Adjuvant Therapeutic According to NCCN Guideline |
|
|
| Active, not recruiting | 3 | 306 | RoW | Paclitaxel or docetaxel + Cisplatin or carboplatin | Huazhong University of Science and Technology, Women's Hospital School Of Medicine Zhejiang University, Qilu Hospital of Shandong University, Obstetrics & Gynecology Hospital of Fudan University, First Affiliated Hospital of Chongqing Medical University, Hunan Cancer Hospital, The Third Xiangya Hospital of Central South University | Uterine Cervical Neoplasms, Cervical Cancer | 01/26 | 01/26 | | |
NCT04733820: Clinical Efficacy of Adjuvant Chemotherapy in Patients With Locally Advanced Cervical Cancer Who Did Not Meet the NCCN Guidelines for Adjuvant Treatment After NACT Combined With Surgery |
|
|
| Recruiting | 3 | 340 | RoW | Adjuvant chemotherapy | Huazhong University of Science and Technology, Women's Hospital School Of Medicine Zhejiang University, Qilu Hospital of Shandong University, Obstetrics & Gynecology Hospital of Fudan University, First Affiliated Hospital of Chongqing Medical University, Hunan Cancer Hospital, The Third Xiangya Hospital of Central South University | Uterine Cervical Neoplasms, Cervical Cancer | 02/28 | 02/28 | | |
| Recruiting | 2/3 | 440 | RoW | Camrelizumab, Cisplatin, Nab paclitaxel, Radical surgery, external beam radiation therapy (EBRT) + brachytherapy | Tongji Hospital, Southwest Hospital, China, Women Hospital, School of Medicine, Zhejiang University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Qilu Hospital of Shandong University, Beijing Friendship Hospital, Tianjin Medical University General Hospital, West China Second University Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Xiangya Hospital of Central South University, Gansu Provincial Maternal and Child Health Care Hospital, Zhejiang Cancer Hospital, Shengjing Hospital, Cancer Hospital of Guangxi Medical University | Cervical Cancer, Locally Advanced Cervical Cancer, Concurrent Chemoradiotherapy, Neoadjuvant Chemoimmunotherapy | 03/31 | 03/31 | | |
NACI, NCT04516616: Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer |
|
|
| Active, not recruiting | 2 | 85 | RoW | Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles) | Huazhong University of Science and Technology, Women's Hospital School Of Medicine Zhejiang University, Qilu Hospital of Shandong University, Obstetrics & Gynecology Hospital of Fudan University, First Affiliated Hospital of Chongqing Medical University, Army Medical University, China, Peking University People's Hospital, Tianjin Medical University General Hospital, The Second Affiliated Hospital of Harbin Medical University, Chongqing University Cancer Hospital, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial) | Uterine Cervical Neoplasm, Uterine Cervical Cancer, Cervical Cancer | 04/23 | 07/28 | | |
NCT04590599: A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy |
|
|
| Completed | 2 | 205 | RoW | IBI310, Placebo, Sintilimab, IBI308 | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Cervical Cancer | 11/23 | 11/23 | | |
| Recruiting | 2 | 40 | RoW | Camrelizumab, Cisplatin, Nab paclitaxel, biopsy | Tongji Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Women Hospital, School of Medicine, Zhejiang University, Third Military Medical University, Beijing Friendship Hospital, Sichuan Cancer Hospital and Research Institute, Tianjin Medical University, West China Second University Hospital, Xiangya Hospital of Central South University, Qilu Hospital of Shandong University, Gansu Cancer Hospital, Zhejiang Cancer Hospital, Shengjing Hospital, Anhui Provincial Cancer Hospital | Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Fertility Preservation | 12/25 | 12/30 | | |
NCT06289751: Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer |
|
|
| Recruiting | 2 | 50 | RoW | Cadonilimab, Cadonilimab Injection, AK104, Paclitaxel-albumin, Injectable paclitaxel (albumin bound), Cisplatin, Cisplatin injection, Extrafascial hysterectomy, Radical hysterectomy, Cone biopsy | Tongji Hospital, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Women Hospital, School of Medicine, Zhejiang University, Southwest Hospital, China, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sichuan Cancer Hospital and Research Institute, Qilu Hospital of Shandong University, Beijing Friendship Hospital, Tianjin Medical University, West China Second University Hospital, Xiangya Hospital of Central South University, Gansu Provincial Maternal and Child Health Care Hospital, Zhejiang Cancer Hospital, Shengjing Hospital | Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy, Extrafascial Hysterectomy | 03/26 | 01/31 | | |
| Recruiting | 2 | 40 | RoW | Camrelizumab, SHR-1210, Paclitaxel-albumin, Injectable paclitaxel (albumin bound), Cisplatin, Cisplatin injection, radical surgery | Tongji Hospital, Southwest Hospital, China, Women Hospital, School of Medicine, Zhejiang University, Anhui Provincial Cancer Hospital, Sichuan Cancer Hospital and Research Institute, Gansu Provincial Maternal and Child Health Care Hospital, Beijing Friendship Hospital, Tianjin Medical University General Hospital, Xiangya Hospital of Central South University, West China Second University Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Zhejiang Cancer Hospital, Shengjing Hospital, Qilu Hospital of Shandong University, Cancer Hospital of Guangxi Medical University | Cervical Cancer, Locally Advanced Cervical Cancer, PD-L1 Negative, Neoadjuvant Chemoimmunotherapy | 12/25 | 12/30 | | |
NCT05325229: A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer |
|
|
| Recruiting | 2 | 94 | RoW | Docetaxel for injection (Albumin-bound), Bevacizumab | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Platinum-resistant Recurrent Ovarian Cancer | 12/24 | 12/24 | | |
NCT03226470: Study of Targeted Therapy Using Transcription Activator-like Effector Nucleases in Cervical Precancerous Lesions |
|
|
| Recruiting | 1 | 40 | RoW | T512, TALEN-T512 | Huazhong University of Science and Technology | Human Papillomavirus-Related Malignant Neoplasm | 02/22 | 06/22 | | |
NCT06336707: HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 1048 | RoW | HS-20089, Adebrelimab, Bevacizumab, Cisplatin / carboplatin | Hansoh BioMedical R&D Company | Advanced Solid Tumors | 04/26 | 04/28 | | |
RWS-01, NCT03955185: Clinical Trial of Minimally Invasive Surgery Versus Abdominal Surgery in Patients With Early Stage Cervical Cancer |
|
|
| Recruiting | N/A | 2000 | RoW | minimally invasive surgery, open abdominal surgery | Ding Ma | Uterine Cervical Neoplasm | 05/22 | 05/24 | | |
| Recruiting | N/A | 590 | RoW | Vaginal brachytherapy, External beam radiotherapy, Observation, Chemoradiation therapy | Women's Hospital School Of Medicine Zhejiang University, Tongji Hospital, Qilu Hospital of Shandong University, Obstetrics & Gynecology Hospital of Fudan University, Sun Yat-sen University, Peking University People's Hospital, Shanghai First Maternity and Infant Hospital, Xiangya Hospital of Central South University, Anhui Provincial Cancer Hospital, Ningbo Women & Children's Hospital, Ningbo No. 1 Hospital | Endometrial Cancer Stage I, Endometrial Cancer Stage II | 12/24 | 01/27 | | |
NCT05570331: Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women |
|
|
| Recruiting | N/A | 2200 | RoW | HPV integration test | Ding Ma | HPV Infection, Cervical Cancer | 02/23 | 12/25 | | |
NCT04974424: Early Warning Model of Susceptibility and High-risk Population of Cervical Cancer Related to HPV |
|
|
| Recruiting | N/A | 20000 | RoW | | Huazhong University of Science and Technology, Women's Hospital School Of Medicine Zhejiang University, Obstetrics & Gynecology Hospital of Fudan University, Qilu Hospital of Shandong University, Wuhan Central Hospital, Third Military Medical University, Xiangyang Central Hospital, Shenzhen Second People's Hospital | Uterine Cervical Neoplasm, Uterine Cervical Cancer, Cervical Cancer | 12/23 | 12/23 | | |
| Wang, Shixuan |
NCT04501744: A Study of M701 (EpCAM and CD3) in Malignant Ascites |
|
|
| Recruiting | 1 | 42 | RoW | Cohort 1 of M701, Cohort 2 of M701, Cohort 3 of M701, Cohort 4 of M701, Cohort 5 of M701, Cohort 6 of M701, Cohort 7 of M701 | Wuhan YZY Biopharma Co., Ltd. | Malignant Ascites, Cancer | 01/21 | 06/21 | | |
NCT05459493: A Clinical Study of Chinese Herbal Compound TJAOA101 in Therapy of Diminished Ovarian Reserve |
|
|
| Not yet recruiting | 1 | 100 | RoW | TJAOA101 | Tongji Hospital | Diminished Ovarian Reserve | 11/23 | 11/23 | | |
NCT05522634: A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency |
|
|
| Not yet recruiting | 1 | 100 | RoW | TJAOA101 | Tongji Hospital | Premature Ovarian Failure | 11/23 | 11/24 | | |
NCT06234670: Risk Factors and A Prediction Model of Recurrence of Uterine Fibroids |
|
|
| Not yet recruiting | N/A | 3200 | RoW | No intervertion | Wenwen Wang, Tongji Hospital | Uterine Fibroid, Recurrence | 01/25 | 01/25 | | |
NCT06020924: The Effects of Uterine Fibroids on Pregnancy in Women |
|
|
| Recruiting | N/A | 1658 | RoW | No intervention | Wenwen Wang, Huazhong University of Science and Technology, Shandong University, Peking University People's Hospital | Female Infertility, Uterine Fibroid | 11/25 | 11/25 | | |
NCT05840042: Epidemiology and Risk Factors of Uterine Fibroids in China |
|
|
| Not yet recruiting | N/A | 20000 | NA | | Shixuan Wang, Women's Hospital School Of Medicine Zhejiang University, Tongji Hospital, First Affiliated Hospital, Sun Yat-Sen University, West China Hospital, Fourth Hospital of Shijiazhuang City | Uterine Fibroid | 12/25 | 12/26 | | |
NCT05665010: Precise Stratification of Genetic Risk of Ovarian Function Impairment |
|
|
| Recruiting | N/A | 1000 | RoW | Genetic susceptibility | Tongji Hospital | Premature Ovarian Insufficiency, Diminished Ovarian Reserve, Early Menopause | 10/23 | 10/24 | | |
| Yuan, Xianglin |
| Recruiting | 4 | 40 | RoW | Hetrombopag Olamine | Huazhong University of Science and Technology | Malignant Tumors of the Digestive System, Trombocitopenia | 10/23 | 12/23 | | |
NCT03236649: The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects |
|
|
| Terminated | 3 | 89 | RoW | Icaritin, Sorafenib Tosylate Tablets | Beijing Shenogen Biomedical Co., Ltd, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Eastern Theater General Hospital,QinHuai District Medical Area, Peking University Cancer Hospital & Institute, Chinese PLA General Hospital, Beijing Hospital, General Hospital of Chinese Armed Police Forces, Guang'anmen Hospital of China Academy of Chinese Medical Sciences, Jinan Central Hospital, Linyi Cancer Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China, Nanfang Hospital of Southern Medical University, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Tianjin Medical University Cancer Institute and Hospital, The Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, The First Hospital of Jilin University, 307 Hospital of PLA, Fudan University, Henan Cancer Hospital, Jilin Provincial Tumor Hospital, First Affiliated Hospital of Harbin Medical University, First Affiliated Hospital Bengbu Medical College, The First Affiliated Hospital of Soochow University, Tongji Hospital, Beijing YouAn Hospital | Hepatocellular Carcinoma (HCC) | 02/22 | 02/22 | | |
NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression |
|
|
| Recruiting | 3 | 351 | RoW | RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan | RemeGen Co., Ltd. | Gastric Cancer, HER2 Overexpressing Gastric Carcinoma | 12/24 | 06/25 | | |
GAPSO, NCT03801668: Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma |
|
|
| Recruiting | 3 | 294 | RoW | Albumin-bound Paclitaxel plus S-1, Oxaliplatin plus S-1 | Huazhong University of Science and Technology, CSPC Ouyi Pharmaceutical Co., Ltd. | Gastric Cancer | 12/22 | 03/23 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
NCT05918094: Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma |
|
|
| Recruiting | 3 | 540 | RoW | Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab | Sun Yat-sen University | Gastric Cancer | 12/26 | 12/28 | | |
NCT05687357: Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma |
|
|
| Recruiting | 2b | 140 | RoW | Tislelizumab, S-1, Oxaliplatin, Nab paclitaxel, Radiation | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Gastric Cancer, Gastroesophageal-junction Cancer | 02/27 | 08/27 | | |
NCT04603040: A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers |
|
|
| Recruiting | 2 | 100 | RoW | Toripalimab, Tuoyi | Shanghai Junshi Bioscience Co., Ltd. | Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy | 12/22 | 03/23 | | |
NCT05438108: SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC |
|
|
| Recruiting | 2 | 30 | RoW | SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab | Huazhong University of Science and Technology | Metastatic Colorectal Cancer | 01/23 | 01/24 | | |
NCT04294784: Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer |
|
|
| Terminated | 2 | 58 | RoW | Albumin-bound Paclitaxel Plus SHR-1210 (PD-1 inhibitor), Albumin-bound Paclitaxel | Huazhong University of Science and Technology | Gastric Cancer, GastroEsophageal Cancer | 11/23 | 11/23 | | |
NCT06168786: Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC |
|
|
| Recruiting | 2 | 40 | RoW | Fruquintinib, Cadonilimab, SBRT | Huazhong University of Science and Technology | Colorectal Cancer | 02/26 | 02/27 | | |
NCT06516445: SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC |
|
|
| Recruiting | 2 | 33 | RoW | SCRT, Camrelizumab, Fluzoparib, CAPEOX | Huazhong University of Science and Technology | Colorectal Cancer | 06/25 | 06/26 | | |
NCT06199895: Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer |
|
|
| Recruiting | 2 | 25 | RoW | Paclitaxel Polymeric Micelles for Injection | Liu Huang | Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Stomach Cancer, Esophageal Carcinoma, Breast Cancer | 11/25 | 11/25 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT03941574: A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy |
|
|
| Recruiting | 2 | 108 | RoW | HLX10 | Shanghai Henlius Biotech | MSI-H Solid Malignant Tumor | 05/24 | 06/26 | | |
NCT06632262: A Phase 2 Clinical Study of ABSK061 and ABSK043 |
|
|
| Not yet recruiting | 2 | 202 | RoW | ABSK061 + ABSK043, ABSK061+ABSK043 in combination with CAPOX | Abbisko Therapeutics Co, Ltd | HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors | 11/29 | 06/30 | | |
NCT05934331: A LM-302 Combined With Toripalimab Phase II Study |
|
|
| Recruiting | 2 | 276 | RoW | LM302+Toripalimab, LM302+JS001 | LaNova Medicines Zhejiang Co., Ltd. | Gastric Cancer, Pancreatic Cancer | 07/25 | 01/26 | | |
CT041-ST-01, NCT04581473: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection |
|
|
| Recruiting | 1/2 | 192 | RoW | CT041 autologous CAR T-cell injection, CAR T-cell injection, Physician's Choice（Paclitaxel or Irinotecan or Apatinib or Anti-PD-1 antibody）, Best support care(BSC) | CARsgen Therapeutics Co., Ltd., Peking University Cancer Hospital & Institute, Fudan University | Gastric Adenocarcinoma, Pancreatic Cancer, Gastroesophageal Junction Adenocarcinoma | 06/24 | 06/38 | | |
NCT06592287: The Combination of Adebrelimab, Apatinib, and Lrinotecan Liposome for Second-line Treatment of Advanced Gastric Cancer |
|
|
| Not yet recruiting | 1/2 | 66 | RoW | Adebrelimab + Apatinib + Lrinotecan liposome | Xianglin Yuan | Advanced Gastric Cancer | 09/25 | 09/26 | | |
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies |
|
|
| Recruiting | 1/2 | 1300 | Canada, US, RoW | SKB264 | Klus Pharma Inc. | Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer | 08/25 | 07/26 | | |
KYM901, NCT04805307: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901 |
|
|
| Recruiting | 1 | 162 | RoW | CMG901 | Keymed Biosciences Co.Ltd | Advanced Solid Tumor, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Pancreatic Cancer | 05/24 | 10/24 | | |
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT02490319: Study on the Biological Prediction Models of Radiation Pneumonitis |
|
|
| Recruiting | N/A | 300 | RoW | | Huazhong University of Science and Technology | Radiation Pneumonitis | 07/23 | | | |
NCT06551207: Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC |
|
|
| Recruiting | N/A | 80 | RoW | Fruquintinib, Cadonilimab, SBRT | Liu Huang | Metastatic Colorectal Cancer | 12/26 | 12/27 | | |
NCT05448703: A Study on Predictive Models and Clinical Outcome of Radiation Pneumonitis |
|
|
| Recruiting | N/A | 300 | RoW | Blood Samples for Biomarkers | Huazhong University of Science and Technology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jingjiang People' Hospital | Radiation Pneumonitis | 09/26 | 09/26 | | |
| Chu, Qian |
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies |
|
|
| Completed | 3 | 159 | RoW | SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592 | FibroGen | Chemotherapy Induced Anemia | 04/23 | 04/23 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
NCT06498479: ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 460 | RoW | HS-20093, Topotecan | Hansoh BioMedical R&D Company | Small Cell Lung Cancer | 09/26 | 05/27 | | |
NCT05767892: YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations |
|
|
| Not yet recruiting | 3 | 350 | RoW | YK-209A tablet, Pemetrexed+carboplatin/Cisplatin | Suzhou Puhe Pharmaceutical Technology Co., LTD | Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | 07/25 | 12/26 | | |
TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. |
|
|
| Recruiting | 3 | 518 | RoW | TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non-small Cell Lung Cancer | 08/25 | 12/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT04106180: SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC |
|
|
| Recruiting | 2 | 63 | RoW | GM-CSF, Sintilimab, SBRT, Stereotactic body radiation therapy | Fudan University | NSCLC Stage IV | 08/22 | 08/23 | | |
CAPSTONE, NCT04888429: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma |
|
|
| Recruiting | 2 | 28 | RoW | Camrelizumab, SHR-1210, Famitinib, SHR-1020 | Qian Chu, Jiangsu HengRui Medicine Co., Ltd. | Sarcomatoid Carcinoma of Lung | 12/24 | 06/25 | | |
|
ARISE, NCT04354961: Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 13 | RoW | Almonertinib, Investigational Product | Fujian Cancer Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Pulmonary Adenosquamous Carcinoma | 12/23 | 06/25 | | |
ACHELOUS, NCT06001151: Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative |
|
|
| Recruiting | 2 | 49 | RoW | Cadonilimab, AK104, Pemetrexed, Carboplatin | Qian Chu, Akeso Pharmaceuticals, Inc. | Carcinoma, Non-Small-Cell Lung | 08/25 | 08/27 | | |
NCT06020066: SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI |
|
|
| Recruiting | 2 | 202 | RoW | EGFR-TK Inhibitor, Stereotactic radiotherapy | Fudan University | Brain Metastases, Non-small Cell Lung Cancer | 08/28 | 08/29 | | |
NCT05329298: A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 90 | RoW | BPI-361175 | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 06/23 | 12/23 | | |
| Recruiting | 1/2 | 127 | RoW | TQB2618 injection and TQB2450 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumor | 12/23 | 06/24 | | |
NCT05789602: A Study of BPI-460372 in Advanced Solid Tumor Patients |
|
|
| Recruiting | 1 | 82 | RoW | BPI-460372 | Betta Pharmaceuticals Co., Ltd. | Advanced Solid Tumor | 04/25 | 04/26 | | |
NCT05513664: Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | N/A | 80 | RoW | Osimertinib | Shanghai JMT-Bio Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer, EGFR Exon20 Insertion Mutations | 06/23 | 08/23 | | |
NCT04766515: Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms |
|
|
| Recruiting | N/A | 1500 | RoW | | Fudan University | Cancer | 08/23 | 08/25 | | |
| Wang, Shaogang |
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) |
|
|
| Active, not recruiting | 3 | 900 | Europe, Canada, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib | Eli Lilly and Company | Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6 | 02/24 | 10/27 | | |
NCT04691804 / 2020-006063-28: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer |
|
|
| Active, not recruiting | 3 | 496 | Europe, US, RoW | Fuzuloparib , Abiraterone acetate and Prednisone, SHR3162, Fuzuloparib Placebo， Abiraterone acetate and Prednisone | Jiangsu HengRui Medicine Co., Ltd. | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 12/26 | 12/26 | | |
| Active, not recruiting | 2/3 | 350 | Europe, Japan, US, RoW | Abemaciclib, LY2835219, Abiraterone Acetate, Prednisone, Placebo | Eli Lilly and Company | Prostate Cancer | 01/24 | 06/26 | | |
NCT05248789: OH2 Oncolytic Viral Therapy in Advanced Bladder Cancer |
|
|
| Recruiting | 2 | 45 | RoW | OH2 injection | Binhui Biopharmaceutical Co., Ltd. | Advanced Bladder Carcinoma | 07/25 | 12/25 | | |
NCT04492293: An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer |
|
|
| Recruiting | 2 | 115 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Bladder Urothelial Cancer | 12/24 | 06/25 | | |
NCT06378242: To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2 |
|
|
| Recruiting | 1/2 | 24 | RoW | Disitamab Vedotin for injection, RC48 | RemeGen Co., Ltd. | High-risk Non-muscle Invasive Bladder Cancer | 03/29 | 12/29 | | |
NCT06708936: KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study |
|
|
| Not yet recruiting | 1 | 12 | RoW | KSD-201 | Kousai Bio Co., Ltd. | Clear Cell Renal Cell Carcinoma (ccRCC) | 11/26 | 11/27 | | |
NCT06725212: Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia |
|
|
| Recruiting | N/A | 126 | RoW | Water Vapor Thermal Ablation, Water Vapor Ablation, Cystoscopy | Medtecx Co Ltd. | Benign Prostatic Hyperplasia | 06/25 | 06/26 | | |
NCT05812482: Treatment of Urethral Stricture With Urethral Drug Ball |
|
|
| Recruiting | N/A | 150 | RoW | Drug balloon dilatation, Direct vision internal urethrotomy (DVIU) | Lepu Medical Technology (Beijing) Co., Ltd. | Urethral Stricture Less Than 2 cm | 10/24 | 02/25 | | |
